MACNICA, Inc. (headquarters: Yokohama, Kanagawa, Japan; President: Kazumasa Hara; hereinafter “Macnica”), a technology provider for semiconductors, network devices, cyber security, and AI/IoT, is pleased to announce a capital and business alliance and exclusive distribution agreement with Arblet (headquarters: Shibuya-ku, Tokyo, Japan; President: Koshinobu Shimizu; hereinafter "Arblet") and has started joint effort to tackle chronic (lifestyle-related) diseases through 24-hour vital monitoring.
In an age when the super-aging society is in full swing, a system that enables more people to have a longer and higher quality of life is required. Macnica aims to improve the quality of life (QOL) of each individual and innovate the efficient use of medical resources by using advanced technology to convert the vital changes in everyday life to data on which is difficult to realize by traditional medical care in the past. Macnica will utilize strengths which had been nurtured as a technology provider and develop solutions to prevent, treat, and prognose lifestyle-related diseases with Arblet.
By using a wrist-worn wearable device (hereinafter "Arblet device") and analysis algorithms on the cloud, various vital data (blood pressure*1, pulse rate, wrist surface temperature, respiratory rate, stress, sleep, etc.) and behavioral information of users can be monitored simultaneously 24 hours a day. In particular, the cuff-less blood pressure measurement enables continuous monitoring of blood pressure during sleep as well as blood pressure per beat. By combining these data with the results of various medical researches, Arblet’s solution aims to provide a service that can detect physical or mental stress and signs of diseases. It also provides emergency alerts and prediction of future disease risks not only to people with health concerns but also to healthy people.
The Arblet device is equipped with advanced semiconductor sensors and transmits sensor data to the cloud via edge terminals such as smartphone, and the system is configured to process and store data using analysis algorithms in the cloud. By transferring all the sensor data to the cloud and analyzing the data on the cloud instead of the edge terminal, it is possible to calculate vital data and behavioral information in sync. The architecture also makes it possible to acquire new vital data retrospectively by developing additional algorithms in the cloud.
(*1) Arblet plans to include the blood pressure related funcions which can be used as a medical device. (Patented)）
Dr. Takuya Kishi, Professor, Department of Cardiovascular Medicine, International University of Health and Welfare Graduate School of Medicine, and the Chairman of the Committee on Next Generation Hypertension, Japanese Society of Hypertension, comments on this joint endeavor.
“Hypertension is the most common lifestyle-related disease, with 43 million patients in Japan. It is also the most important risk factor for cerebral cardiovascular disease, which is the leading cause of death among the elderly, along with malignant tumors. However, blood pressure is measured only in hospitals or at home once or twice a day, which is not enough to understand the condition of hypertension and to determine the effect of treatment. 33% of hypertension patients do not even know their own blood pressure, which is a serious problem. To change this, it is required to understand and treat hypertension by blood pressure data linked with life logs with data measured with cuffless wearable devices, and to create a new hypertension science by big data analysis. As a clinician, I have high expectations for Arblet's vision of the future.”
Macnica's Healthcare Business
In response to social issues such as reduction of social security expenses, extension of healthy life expectancy, and establishment of a lifelong active society against the backdrop of a super-aging society, Macnica is working on healthcare business by utilizing advanced technology and data. Macnica will focus on the prevention of mental health and chronic diseases (lifestyle-related diseases), including depression, which is feared to expand due to the COVID-19 pandemic, and will support people to lead rich and fulfilling lives both mentally and physically.
Macnica has the ability to source advanced technologies accumulated through nearly 50 years of trading business. In addition, it has semiconductor technologies that form the core of technological innovation, IT technologies centered on data management and security, and AI capability with a community of approximately 80 data scientists in the Group and 25,000 data scientists worldwide. Macnica is collecting vital and mental data and developing AI driven healthcare solutions.
- The names of companies and products mentioned herein are trademarks or registered trademarks of Macnica, Inc. and their respective companies.
- The information contained in this news release is current as of the date of publication. The information in the news release is current as of the date of the announcement and is subject to change without notice.